Vemtoberant

DB21607InvestigationalSmall molecule

Vemtoberant is a small molecule drug. Vemtoberant is under investigation in clinical trial NCT05139615 (A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult... Vemtoberant has a monoisotopic molecular weight of 619.2 Da.

Formula / weight: C₂₉H₃₇N₃O₈S₂ · 619.75 g/mol (avg)
Code names: APD-418

Resolves to

Compound

UNII4IJ6WR3BW8CAS2169905-68-2ChEMBLCHEMBL5314946ChEBI759637PubChem132225057

Structure

InChIKeyPVXLIOIISUUKOQ-YADHBBJMSA-NSMILESCCN1C=C(C(=O)C2=CC=CC=C12)S(=O)(=O)N1CCC2(C[C@H](CO2)NC[C@H](O)COC2=CC(=CC=C2)S(C)(=O)=O)CC1

Targets

P13945ADRB3

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Vemtoberant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account